A Phase 2 interventional study of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation and Hematologic and Lymphocytic Disorder, sponsored by M.D. Anderson Cancer Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment
\<75% participation
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 134th largest by enrollment of the 211 interventional ones that give a count, is one of 9 that started in 2019, is one of 105 in phase 2, and was the 99th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 133 · Phase 3 31 · Phase 4 3
First in 2000; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 211 interventional studies. Of the 100 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 214 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
197 studies in Leukemia, Myeloid, Acute by M.D. Anderson Cancer Center: 34 open now, 50 under way, 1 of them phase 3. Of 136 finished, 86 (63%) have results posted.
Among the 197 studies in Leukemia, Myeloid, Acute by M.D. Anderson Cancer Center, this one is the 98th largest by enrollment of the 191 interventional ones that give a count, is one of 9 that started in 2019, is one of 74 in phase 2, and was the 155th registered.
M.D. Anderson Cancer Center’s Leukemia, Myeloid, Acute studies by the year they started, since 1994.
26 of the studies testing azacitidine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT06783790Institute of Hematology & Blood Diseases Hospital, ChinaAvapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | 2026-12 |
| NCT06066905Guangdong Provincial People's HospitalA Study of Chidamide With AZA in MRD Positive AML After Transplant | 2026-12 |
Add all 26 to your calendar (.ics) → With an account.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, from their registry updates:
Among M.D. Anderson Cancer Center’s 197 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
PRIMARY OBJECTIVES:
I. To assess relapse-free survival (RFS) of patients (pts) with acute myeloid leukemia (AML) treated with 5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission.
SECONDARY OBJECTIVES:
I. To assess modified RFS of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
II. To assess overall survival (OS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
III. To assess event-free survival (EFS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
IV. To assess the duration of remission (CRd) of pts with AML treated 5-azacytidine combined with venetoclax as maintenance therapy.
V. To assess toxicity and safety of 5-azacytidine combined with venetoclax as maintenance therapy in pts with AML.
VI. To assess the effects of 5-azacytidine combined with venetoclax on dynamics of minimal residual disease (MRD) and their relationship to outcomes.
OUTLINE:
Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 1 hour daily on days 1-5, and venetoclax orally (PO) daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6-12 months thereafter.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
This study's enrollment of 36 is close to the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hematologic Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function as follows:
Adequate BM reserve:
For females of childbearing age, they may participate if they:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Drug: Azacitidine · Drug: Venetoclax
Given SC or IV
Also known as: 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza
Given PO
Also known as: ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Relapse-free survival (RFS)
The study will be continuously monitored for the primary endpoint, RFS, using the method of Thall, Wooten, and Tannir (2005). Will also summarize the posterior distribution of lambda-E (i.e., median RFS) assuming posterior mean and 95% credible interval.
Time frame: From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), assessed for up to 10 years
Incidence of toxicity
Toxicities are defined as any treatment -related clinically significant grade 3 or 4 non-hematologic adverse events occurred during cycles 1-2 of the trial. Will continuously monitor treatment-related toxicities using the Bayesian approach of Thall, Simon, Estey (1995).
Time frame: Up to 10 years
Modified RFS
Distribution assessed using Kaplan-Meier method.
Time frame: Time from enrollment on study until date of first objective documentation of relapse or death, assessed for up to 10 years
Overall survival (OS)
Distribution assessed using Kaplan-Meier method.
Time frame: From the start of study treatment until date of death due to any cause, assessed for up to 10 years
Event free survival (EFS)
Distribution assessed using Kaplan-Meier method.
Time frame: From the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, assessed for up to 10 years
Complete remission duration (CRd)
Distribution assessed using Kaplan-Meier method.
Time frame: Time from CR or CRi until date of first objective documentation of confirmed relapse, assessed for up to 10 years
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2019 to primary completion in Oct 2026, 84 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2030 → Oct 2026 and completion Oct 2030 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
\<75% participation
\<75% participation
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azacitidine · Venetoclax